OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
Mitchell F Brin, Suresh Durgam, Arlene Lum, Lynn James, Jeen Liu, Michael E Thase, Armin Szegedi, Mitchell F Brin, Suresh Durgam, Arlene Lum, Lynn James, Jeen Liu, Michael E Thase, Armin Szegedi
Abstract
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS); secondary endpoints were Clinical Global Impressions-Severity and 17-item Hamilton Depression Rating Scale at week 6. A total of 255 adult females were treated. OnabotA 30 U approached significance compared to placebo on MADRS (mixed-effect model repeated measures least-squares mean difference: -3.7; P = 0.053) and reached significance [least-squares mean differences: -3.6 to -4.2; P < 0.05 (two-sided)] at weeks 3 and 9. Secondary endpoints were also significant at several time points. At week 6, onabotA 50 U did not separate from placebo in any parameters. OnabotA was generally well-tolerated: the only treatment-emergent adverse events reported in ≥5% in either onabotA group, and more than matching placebo were headache, upper respiratory infection, and eyelid ptosis. OnabotA 30 U, administered in a standardized injection pattern in a single session, had a consistent efficacy signal across multiple depression symptom scales for 12 or more weeks. OnabotA 30 U/placebo MADRS differences of (observed ANCOVA) ≥4.0 points (up to week 15) and ≥2.0 points (weeks 18-24) agree with the 2-point change threshold considered clinically relevant in MDD. OnabotA is a local therapy and is not commonly associated with systemic effects of conventional antidepressants and may represent a novel treatment option for MDD.
Figures
References
- Almeida ART, Kadunc BV, Marques ERMC. Glabellar wrinkles: a pilot study of contraction patterns. Surg Cosmet Dermatol. 2010; 2:23–28
- American Psychiatric Association ; American Psychiatric Association Diagnostic and statistical manual of mental disorders. 20004th ed. text rev, Washington, DC: American Psychiatric Association
- Baldessarini RJ, Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry. 1990; 47:191–192
- Baldessarini RJ, Forte A, Selle V, Sim K, Tondo L, Undurraga J, et al. Morbidity in depressive disorders. Psychother Psychosom. 2017; 86:65–72
- BOTOX Cosmetic ; BOTOX Cosmetic (onabotulinumtoxinA) [package insert]. 2015, Irvine, CA: Allergan plc
- Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297:1683–1696
- Brin MF, Boodhoo TI, Pogoda JM, James LM, Demos G, Terashima Y, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009; 61:961–970 e111
- Burstein R, Giesler GJ., Jr Retrograde labeling of neurons in spinal cord that project directly to nucleus accumbens or the septal nuclei in the rat. Brain Res. 1989; 497:149–154
- Burstein R, Potrebic S. Retrograde labeling of neurons in the spinal cord that project directly to the amygdala or the orbital cortex in the rat. J Comp Neurol. 1993; 335:469–485
- Burstein R, Dado RJ, Giesler GJ., Jr The cells of origin of the spinothalamic tract of the rat: a quantitative reexamination. Brain Res. 1990; 511:329–337
- Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014; 34:853–869
- Clayton A, Keller A, Mcgarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006; 91:27–32
- Clayton AH, McGarvey EL, Clavet GJ. The changes in sexual functioning questionnaire (CSFQ): development, reliability, and validity. Psychopharm Bull. 1997a; 33:731–745
- Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharm Bull. 1997b; 33:747–753
- De Almeida AR, Da Costa Marques ER, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. Dermatol Surg. 2012; 38:1506–1515
- Demyttenaere K, Enzlin P, Dewé W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psych. 2001; 62:30–33
- Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014; 6:851–859
- Ekman P, Friesen WV. Facial action coding system: a technique for the measurement of facial movement. 1978, Palo Alto, CA: Consulting Psychologist Press
- Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003; 53:649–659
- Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014; 52:1–6
- Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006; 32:645–649; discussion 64950
- Guy W. The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, MD: National Institute of Mental Health, 218–222. DHEW Publication No. 76-338
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56–62
- Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018; 75:336–346
- Hennenlotter A, Dresel C, Castrop F, Ceballos-Baumann AO, Wohlschlager AM, Haslinger B. The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex. 2009; 19:537–542
- Izard C. Facial expressions and the regulation of emotions. J Person Soc Psych. 1990; 58:487–498
- Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. ; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289:3095–3105
- Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. Ann Epidemiol. 2012; 22:112–119
- Magid M, Reichenberg JS, Poth PE, Robertson HT, Laviolette AK, Kruger THC, Wollmer MA. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75:837–844
- Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol. 1998; 400:125–144
- Mcintosh D. Facial feedback hypotheses: evidence, implications, and directions. Motivation and Emotion. 1996; 20:121–147
- Medic G, Higashi K, Littlewood KJ, Diez T, Granström O, Kahn RS. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2013; 9:119–131
- Merikangas KR, Ames M, Cui L, Stang PE, Ustun B, Von Korff M, Kessler R C. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psych. 2007; 64:1180–1188
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382–389
- Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009; 24:111–118
- Pollack MH, Rosenbaum JF. Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psych. 1987; 48:3–8
- Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168:1266–1277
- Pribitkin EA, Greco TM, Goode RL, Keane WM. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. Arch Otolaryngol Head Neck Surg. 1997; 123:321–326
- Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13:497–504
- Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014; 12:535–549
- Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163:1905–1917
- Schwartz GE, Fair PL, Salt P, Mandel MR, Klerman GL. Facial muscle patterning to affective imagery in depressed and nondepressed subjects. Science. 1976; 192:489–491
- Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997; 12:232–241
- Thaipisuttikul P, Ittasakul P, Waleeprakhon P, Wisajun P, Jullagate S. Psychiatric comorbidities in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10:2097–2103
- Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358:252–260
- Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports. 2007; 9:449–459
- Wollmer MA, De Boer C, Kalak N, Beck J, Götz T, Schmidt T, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012; 46:574–581
Source: PubMed